Supported by the DOSIsoft team, the “QUANTHYR” module has been integrated into PLANET® Dose – a dosimetry platform dedicated to treatment planning and follow-up through Radionuclide Molecular Radiotherapy (MRT). This integration enhances PLANET® Dose by introducing a new application for the personalized management of patients with benign thyroid diseases.

DOSIsoft S.A.’s business development plan includes a clinical evaluation phase involving partner centers, a pre-launch phase featuring various congresses in France and the submission and attainment of CE mark.


“We’re enthusiastic about the opportunity to help physicians and patients with benign thyroid pathology benefit from personalized treatment. PLANET® Dose-QUANTHYR represents a unique innovation in the world, aligning with our vision of personalized medicine, and reinforcing our commitment to physicians towards the benefit of patients”, says Marc USZYNSKI, CEO at DOSIsoft S.A.

“The introduction of quantification in thyroid scintigraphy images, combined with biological and echography volumetry, provides an unparalleled reproducible diagnostic power. By placing the clinical therapeutic objective at the center of the approach, prescribing becomes more accessible and straightforward. QUANTHYR also serves as a radioprotection tool, minimizing activity levels and securing the radiopharmaceutical prescription process”, says Pr Jérôme CLERC, Head of the Nuclear Medicine department at Cochin hospital - AP-HP.


About Assistance Publique - Hôpitaux de Paris / Greater Paris University Hospitals
The leading hospital and university centre (CHU) in Europe, Greater Paris University Hospitals and its 38 hospitals are organized into six hospital-university groups (AP-HP. Centre - Université Paris Cité ; AP-HP. Sorbonne Université ; AP-HP. Nord - Université Paris Cité ; AP-HP. Université Paris Saclay ; AP-HP. Hôpitaux Universitaires Henri Mondor et AP-HP. Hôpitaux Universitaires Paris Seine-Saint-Denis) and are centered around five universities in the Île-de-France region. Closely linked to large research bodies, Greater Paris University Hospitals include eight international hospital-university institutes (Institut du Cerveau, ICAN, IMAGINE, FOReSIGHT, PROMETHEUS, InovAND, reConnect, THEMA) and the largest French health data repository (EDS). As a major stakeholder in applied research and health innovation, Greater Paris University Hospitals hold a portfolio of 750 active patents, and each year its clinicians sign off nearly 11000 scientific publications and over 4,000 research projects are under development, all promoters combined. In 2020, Greater Paris University Hospitals were awarded the Institut Carnot label, which is recognition of the quality of partner research: Carnot@AP-HP offers industrial stakeholders applied and clinical research solutions in the health sector. In 2015, Greater Paris University Hospitals also founded the Greater Paris University Hospitals Research Foundation to support the biomedical and health research performed in all its hospitals. http://www.aphp.fr

Industry Partnerships Homepage